Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KIVU-107
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Organovo Holdings
Deal Size : $92.0 million
Deal Type : Series A Financing
Kivu Bioscience Raises $92M to Advance Antibody-Drug Conjugates
Details : The financing will aims to support the clinical development of multiple antibody-drug conjugate (ADC) programs, which include KIVU-107. It is being evaluated for the treatment of neoplasms.
Product Name : KIVU-107
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : KIVU-107
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Organovo Holdings
Deal Size : $92.0 million
Deal Type : Series A Financing